The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism.
- DOI
- 10.1080/21678707.2020.1791082
- Published
- 2020
- Container
- Expert opinion on orphan drugs
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/21678707.2020.1791082,
title = {The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism.},
author = {Thompson WS and Mondal G and Vanlith CJ and Kaiser RA and Lillegard JB},
year = {2020},
journal = {Expert opinion on orphan drugs},
doi = {10.1080/21678707.2020.1791082},
url = {https://doi.org/10.1080/21678707.2020.1791082}
}RIS
TY - JOUR TI - The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism. AU - Thompson WS AU - Mondal G AU - Vanlith CJ AU - Kaiser RA AU - Lillegard JB PY - 2020 JO - Expert opinion on orphan drugs DO - 10.1080/21678707.2020.1791082 UR - https://doi.org/10.1080/21678707.2020.1791082 ER -
APA
WS, T., G, M., CJ, V., RA, K., & JB, L. (2020). The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism.. Expert opinion on orphan drugs. https://doi.org/10.1080/21678707.2020.1791082
Source records
- pubmed · retrieved 2026-09-26T22:59:16.564Z